Skip to content
All resources

Semax

What Is Semax? Structure, Origin, Evidence and Regulatory Status

CL

By

· 8 min read

A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.

On this page · 6 sections
  1. What is Semax made of?
  2. How is Semax thought to work?
  3. What has Semax been studied for?
  4. Is Semax approved anywhere?
  5. What is Semax commonly confused with?
  6. Frequently asked questions

Semax is a synthetic seven-residue peptide, Met-Glu-His-Phe-Pro-Gly-Pro, made by joining a fragment of adrenocorticotropic hormone, ACTH(4-7), to a stabilising Pro-Gly-Pro tail. It was developed at the Institute of Molecular Genetics in Moscow and is a registered medicine in Russia. Most of its research is in rats: brain BDNF, monoamines and gene expression after experimental stroke. The human record is small, mostly in Russian and not from modern randomised trials. It has no approval in Canada, the US or the EU.

A seven-bead peptide chain in front of a glowing network of neurons
Illustration, not the exact structure: a seven-residue peptide studied in neuroscience.

What is Semax made of?

Two pieces with different jobs. The first four residues, Met-Glu-His-Phe, are positions 4 to 7 of ACTH, from the N-terminal ACTH(4-10) region that Semax was modelled on. The last three, Pro-Gly-Pro, are a "glyproline" tail. Regulatory peptides are usually thought of as unstable in the body, broken down quickly by peptidases. Ashmarin and colleagues, whose author list includes Semax's Moscow developers, argued that glyprolines and Pro-Gly-Pro-containing peptides are far more stable than that, and described Semax and Selank as hybrid or "chimeric" peptides in which a natural active fragment and a stabilising tail are joined (PMID 15837162).

That is why Semax is variously called an ACTH(4-10) analogue and ACTH(4-7)PGP. Both names describe the same molecule: it keeps the length of the natural ACTH(4-10) fragment but replaces its last three residues with the stable tail.

PropertySemax
SequenceMet-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP)
Also calledACTH(4-7)PGP; an ACTH(4-10) analogue
CAS number (PubChem)80714-61-0
Molecular formula (PubChem)C37H51N9O10S
Molecular weight (PubChem)About 814 g/mol
OriginInstitute of Molecular Genetics, Russian Academy of Sciences, Moscow
Evidence stageMostly rodent; small, largely Russian-language human studies
Regulatory statusRegistered in Russia; no Health Canada, FDA or EMA authorisation found

Semax has a close relative from the same institute, Selank, which shares the Pro-Gly-Pro tail but is built on a different parent peptide; see Semax vs Selank. A further-modified version with capped ends, sold as N-acetyl Semax amidate, is a different compound with almost no literature of its own; see N-acetyl Semax amidate vs Semax.

How is Semax thought to work?

No single receptor has been identified, and the proposed mechanisms have widened over time rather than converged. The main threads, all from animal or cell work:

BDNF. Dolotov and colleagues found specific, reversible, calcium-dependent binding of radiolabelled Semax to membranes from rat basal forebrain, and a rise in BDNF protein in that region, but not in the cerebellum, three hours after exposure (PMID 16635254). This is the most cited mechanistic finding. What BDNF is, and why a change in its level is not the same as a functional effect, is covered in BDNF explained.

Monoamines. In rodents, Eremin and colleagues reported that Semax raised striatal levels of the serotonin metabolite 5-HIAA and amplified the dopamine release and locomotor activity produced by amphetamine, while not changing dopamine on its own (PMID 16362768).

Peptidase inhibition. In human serum, Semax and Selank inhibited enkephalin-degrading enzymes, with Semax the more potent of the two in that assay (PMID 11443939). The authors suggested that slowing the breakdown of other regulatory peptides might be part of how both act. It is a test-tube finding, and it has not been tied to an effect in a living system.

Gene expression after experimental stroke. Genome-wide studies in rats with blocked middle cerebral arteries reported that Semax shifted expression of immune and vascular genes (PMID 24661604), and in a reperfusion model it suppressed inflammation-related genes and raised neurotransmission-related ones (PMID 32580520).

The honest summary is that Semax touches several systems in rodent brain and that no one of them has been shown to account for the effects reported. Each thread is examined in Semax neuroprotection.

What has Semax been studied for?

AreaEvidence stageWhat exists
Cerebral ischaemia (stroke)Rodent; small Russian clinical studiesGene-expression and BDNF work in rats; non-randomised patient comparisons
Learning and memoryRodent; small human imaging studiesBehavioural and neurotrophin studies in rats; resting-state fMRI in healthy volunteers
NeurochemistryRodentSerotonin and dopamine system changes
Other (spinal cord injury, amyloid, gut)Rodent or test-tubeSingle studies, unreplicated

Stroke is where the compound started, and where its clinical claims rest. The most cited clinical paper, published in Russian, compared 30 patients with acute ischaemic stroke who received Semax alongside standard care with 80 patients of similar severity treated conventionally, and reported faster recovery on clinical rating scales (PMID 11517472). Patients were not randomised and the comparison group was assembled separately, so the design cannot separate the drug from differences between the groups. The full ischaemia literature is in Semax and cerebral ischaemia.

Cognition is where most English-language interest sits, and where the human data are thinnest. Lebedeva and colleagues scanned 24 healthy volunteers with resting-state fMRI before and after Semax or placebo and reported a larger rostral component of the default mode network in the Semax group (PMID 30225715). That is a change in a brain-imaging pattern in 14 people who received the drug, not a measured change in thinking or memory. The broader cognitive comparison with a different Russian compound is in Semax vs Noopept.

ClinicalTrials.gov lists no registered study with Semax as the intervention, which is itself informative: none of this evidence comes from the registered, prespecified trials that regulators outside Russia would assess.

Is Semax approved anywhere?

In Russia, yes. The Russian drug reference lists a registration for Semax held by the Moscow company Peptogen, and Russian clinical papers describe its use in stroke care. Outside Russia, no. We found no authorisation from Health Canada, the FDA or the EMA, and none of the Russian clinical experience has been reviewed by those regulators. Status in Canada can be checked in the Drug Product Database, and the general framework is set out in peptides and Canadian law.

A Russian registration is a real regulatory fact. It does not transfer to any other jurisdiction, and it does not transfer to material sold for laboratory research, which is not the registered medicine.

What is Semax commonly confused with?

ACTH. Semax contains a four-residue piece of ACTH, not the hormone. It is a short fragment analogue, and findings about ACTH itself, including its adrenal actions, do not describe it.

Selank. Same institute, same tail, same length, different parent peptide and different literature.

N-acetyl Semax amidate. A capped derivative, sold under a similar name, with almost no published research of its own. Findings about Semax do not carry over to it automatically.

A "nootropic" with proven human effects. The word appears in paper titles, but the human evidence for cognition is a handful of small, mostly Russian studies with biomarker or imaging endpoints.

Supplied here for laboratory use: Semax. The laboratory's certificate for each lot is linked from its product page. For laboratory research use only.

The findings above describe the compound in the animals and people studied, not any laboratory reagent. Nothing here is medical, dosing, or therapeutic guidance.

Frequently asked questions

Why is Semax called an ACTH(4-10) analogue? Because it was designed as a stable version of the ACTH(4-10) fragment, a piece of adrenocorticotropic hormone studied for effects on learning in animals. Semax keeps ACTH positions 4 to 7 and replaces positions 8 to 10 with Pro-Gly-Pro. The result has the same seven-residue length as the fragment, with a tail that resists breakdown.

Does Semax act at melanocortin receptors? No specific receptor has been established. ACTH fragments belong to the melanocortin family, but the Semax literature reports specific binding sites in rat brain without identifying the receptor, alongside effects on BDNF, monoamines, peptidases and gene expression. Treating it as a melanocortin agonist goes beyond what the papers show.

Has Semax been tested in randomised trials? Not in any registered randomised trial that we could find. ClinicalTrials.gov lists none. The best-known clinical study, in acute stroke, compared treated patients with a separately assembled control group. Small imaging studies in healthy volunteers used placebo groups but measured brain-network patterns rather than clinical outcomes.

Is Semax legal in Canada? It has no Canadian authorisation as a drug. It is sold here as a laboratory research chemical, not for human use. Its registration in Russia does not change its status in Canada, and Health Canada states that peptides are generally regulated as prescription drugs.

Selected Research References

  1. Ashmarin IP, Samonina GE, Lyapina LA, et al. Natural and hybrid ("chimeric") stable regulatory glyproline peptides. Pathophysiology. 2005;11(4):179-185. pubmed.ncbi.nlm.nih.gov/15837162
  2. Dolotov OV, Karpenko EA, Seredenina TS, et al. Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. Journal of Neurochemistry. 2006;97(Suppl 1):82-86. pubmed.ncbi.nlm.nih.gov/16635254
  3. Eremin KO, Kudrin VS, Saransaari P, et al. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochemical Research. 2005;30(12):1493-1500. pubmed.ncbi.nlm.nih.gov/16362768
  4. Kost NV, Sokolov OIu, Gabaeva MV, et al. Semax and selank inhibit the enkephalin-degrading enzymes from human serum. Bioorganicheskaia Khimiia. 2001;27(3):180-183. pubmed.ncbi.nlm.nih.gov/11443939
  5. Medvedeva EV, Dmitrieva VG, Povarova OV, et al. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics. 2014;15:228. pubmed.ncbi.nlm.nih.gov/24661604
  6. Filippenkov IB, Stavchansky VV, Denisova AE, et al. Novel insights into the protective properties of ACTH(4-7)PGP (Semax) peptide at the transcriptome level following cerebral ischaemia-reperfusion in rats. Genes. 2020;11(6):681. pubmed.ncbi.nlm.nih.gov/32580520
  7. Gusev EI, Skvortsova VI, Miasoedov NF, et al. Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study). Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova. 1997;97(6):26-34. pubmed.ncbi.nlm.nih.gov/11517472
  8. Lebedeva IS, Panikratova YR, Sokolov OY, et al. Effects of Semax on the default mode network of the brain. Bulletin of Experimental Biology and Medicine. 2018;165(5):653-656. pubmed.ncbi.nlm.nih.gov/30225715

All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.